Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Clinical Trial on Effectiveness of Breast Cancer Screening Using 3D Mammography


Breast Cancer

The TMIST is the largest multi-center study of its kind to evaluate whether 3D digital tomosynthesis technology used in conjunction with 2D digital mammography, is more effective at early identification of breast cancer, compared to conventional mammography alone.

Share this!

February 9, 2017 | by Sarah Hand, M.Sc.

The Breast Health Center in Ottawa, Canada, is the latest site to join the lead-in to the Tomosynthesis Mammographic Imaging Screening Trial (TMIST). This site – which will be part of a larger Canada/US study – will be managed by researchers at The Ottawa Hospital Breast Health Centre and the Ottawa Integrative Cancer Centre (OICC).

The TMIST is the largest multi-center study of its kind to evaluate whether 3D digital tomosynthesis technology used in conjunction with 2D digital mammography, is more effective at early identification of breast cancer, compared to conventional mammography alone. Previous studies have shown that 3D mammography is effective at diagnosing breast cancer before it becomes more advanced, while minimizing the number of false positive results.

If the current trial is able to reproduce these results, 3D mammography could be a more effective and less costly tool for breast cancer screening. The lead-in study will enroll just over 6,000 women across Canada, including approximately 2,000 patients at the Ottawa site alone.

Digital breast tomosynthesis composes a 3D image of the breast tissue by layering multiple images taken using low-dose X-rays. The benefit over traditional 2D mammography is that information in the images compiled using tomosynthesis are not superimposed, reducing the risk of physicians missing hard to see tumors.

“Tomosynthesis is the most advanced and exciting technology for mammography,” said Dr. Jean Seely, Head of Breast Imaging at the Breast Health Centre, associate professor at the University of Ottawa and lead investigator of TMIST Lead-In in Ottawa. “When the full study begins, it will be the largest and most important study to evaluate both 3D and 2D mammography technology together. Outcomes of the study will allow us to decide how we move forward from 2D to 3D screening. Our goal is to improve on ways to detect important cancers as early as possible in order to save lives.”

Screening programs using mammography have been very successful at reducing the mortality rate of breast cancer. Women who underwent screening prior to receiving a breast cancer diagnosis showed a mortality rate of six percent at five years post-diagnosis, while those who were not screened had a 15 percent death rate.

However, like most screening technologies, traditional 2D mammography carries an inherent risk of generating false positive results. This occurrence creates unnecessary stress for patients, with over 90 percent of women recalled for additional testing receiving a benign or normal diagnosis. The hope is that tomosynthesis could improve the accuracy of breast cancer detection, by eliminating most false positives.

“We are pleased to collaborate and help fund this critical trial,” said Dugald Seely, naturopathic doctor, Executive Director of the OICC, and co-investigator of TMIST in Ottawa. “Imaging and mammography are stressful events. The OICC is committed to supporting women so that they receive the best diagnostic technology, limiting unnecessary anxiety and ultimately reducing the burden of disease. The screening program is potentially revolutionary and we hope will be more accurate in correctly finding breast cancers that may not otherwise be diagnosed.”

Keywords: Clinical Trial, Breast Cancer, Mammography


Share this with your colleagues!

Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News

New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News

Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub


Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases

Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects

Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance

Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned

Copyright © 2016-2017 Honeycomb Worldwide Inc.